Zoetis announces positive opinion from CVMP for Portela

Zoetis (ZTS) announced that the Committee for Veterinary Medicinal Products of the European Medicines Agency has adopted a positive opinion recommending the granting of marketing authorization for Portela, a new monoclonal antibody therapy intended for the alleviation of pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-nerve growth factor mAb therapy for cats and is designed to provide three months of osteoarthritis pain relief with a single injection, the company stated.